BridgeMD
Compares treatment options for Acute Urinary Retention
Official title Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention.
ClinicalTrials.gov ID: NCT07283484
What this study is testing
- What it's testing
- Acute urinary retention (AUR) is a sudden and painful condition. It occurs when a person is unable to urinate.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- Adult men (≥18 years)
- Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin)
- Mentally competent and able to understand the potential benefits and burdens of study participation
- Provision of written or digital informed consent
You likely can't join if
- Failed prior TWOC within the preceding 30 days
- Initial urinary retention volume \>1500 mL
- Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida)
- History of prostate cancer with ISUP grade group ≥2
- History of active bladder cancer or ongoing surveillance for bladder cancer
- Urinary retention occurring within 72 hours after surgery (postoperative urinary retention)
See the full eligibility criteria
- Adult men (≥18 years)
- Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin)
- Mentally competent and able to understand the potential benefits and burdens of study participation
- Provision of written or digital informed consent
- Failed prior TWOC within the preceding 30 days
- Initial urinary retention volume \>1500 mL
- Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida)
- History of prostate cancer with ISUP grade group ≥2
- History of active bladder cancer or ongoing surveillance for bladder cancer
- Urinary retention occurring within 72 hours after surgery (postoperative urinary retention)
- History of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, or prostate surgery)
- AUR suspected to be caused by bladder stones
- Suspected urethral stricture, clot retention, or urosepsis
- Contraindication to alpha-blocker therapy
The study team makes the final eligibility decision.
Where it's taking place
- Harderwijk, Gelderland, Netherlands
- Nijmegen, Gelderland, Netherlands
- Heerlen, Limburg, Netherlands
- Maastricht, Limburg, Netherlands
- Eindhoven, North Brabant, Netherlands
- Amsterdam, North Holland, Netherlands
- Hoofddorp, North Holland, Netherlands
- Hengelo, Overijssel, Netherlands
- Zwolle, Overijssel, Netherlands
- Groningen, Provincie Groningen, Netherlands
- Leiderdorp, South Holland, Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Harderwijk, Gelderland, Netherlands; Nijmegen, Gelderland, Netherlands; Heerlen, Limburg, Netherlands; Maastricht, Limburg, Netherlands; Eindhoven, North Brabant, Netherlands; Amsterdam, North Holland, Netherlands and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.